Insight Molecular Diagnostics Inc. (IMDX) Net margin 2020–2025
Insight Molecular Diagnostics Inc. (IMDX) net profit margin by fiscal year — reported net income divided by reported revenue.
-1238.5%FY2025 · since FY2020: -2461.5% → -1238.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -1238.5% | +1986.5 pp |
| FY2024 | -3225.0% | -1376.7 pp |
| FY2023 | -1848.4% | +5761.4 pp |
| FY2022 | -7609.8% | -4693.7 pp |
| FY2021 | -2916.2% | -454.6 pp |
| FY2020 | -2461.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMDX financial trends
IMDX RevenueIMDX Net incomeIMDX Gross profitIMDX Gross marginIMDX Operating incomeIMDX Operating marginIMDX Operating cash flowIMDX Free cash flowIMDX Capital expendituresIMDX Return on equityIMDX Stock buybacksIMDX Dividends paidIMDX Total assetsIMDX Total liabilitiesIMDX Shareholders’ equityIMDX overview →